ArticleJACC. Advances2026
Pulmonary Embolism-Attributable Mortality in Patients With Heart Failure in the United States, 2010 to 2020.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContemporary trends in pulmonary embolism (PE)-attributable mortality among U.S. patients with heart failure (HF) remain underexplored.
objectivesThe objective of the study was to evaluate trends in PE-attributable mortality from 2010 to 2020 among US patients with HF, stratified by age, sex, race/ethnicity, urbanicity, and region.
methodsData on PE-attributable mortality in HF patients aged ≥25 years were obtained from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database from January 2010 to December 2020. Age-adjusted mortality rates (AAMRs) were analyzed using joinpoint regression to calculate average annual percentage change with 95% CIs. Concurrent trends in HF prevalence and venous thromboembolism risk factors were assessed using the National Health and Nutrition Examination Survey data set.
resultsBetween 2010 and 2020, 38,129 U.S. patients with HF aged ≥25 years (17,772 men and 20,357 women) died from PE, corresponding to a proportionate mortality of 97.5 per 1,000 deaths (≈9.8%). AAMR linearly increased during this period (average annual percentage change: +4.7%; 95% CI: 3.3%-6.1%; P < 0.001), with no sex differences (P for parallelism = 0.23). The AAMR increased among individuals aged 25 to 65 years, Asian/Pacific Islanders, non-Hispanic/non-Latinx Black individuals, and residents of the Midwest. Although age-adjusted prevalence of HF plateaued overall, HF patients aged with concomitant rises in age-adjusted rates of obesity, prior smoking, atherosclerotic cardiovascular disease, chronic kidney disease, and cancer (P < 0.001 for all).
conclusionsPE-attributable mortality among U.S. patients with HF has risen significantly over the past decade particularly among younger adults, certain ethnoracial groups, and residents of the Midwest.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.